Related Experiment Video

Updated: Aug 21, 2026

A Mouse Model to Investigate the Role of Cancer-Associated Fibroblasts in Tumor Growth
06:35

A Mouse Model to Investigate the Role of Cancer-Associated Fibroblasts in Tumor Growth

Published on: December 22, 2020

The MAPK pathway as a pharmacological target to reprogram cancer-associated fibroblasts and disrupt the stromal

Masaki Arioka1, Fumi Takahashi-Yanaga1

  • 1Department of Pharmacology, School of Medicine, University of Occupational and Environmental Health, Japan.

Biochemical Pharmacology
|August 19, 2026
PubMed

Insights

The tumor microenvironment, including cancer-associated fibroblasts (CAFs), supports tumor growth. Mitogen-activated protein kinase (MAPK) signaling drives CAF differentiation and therapy resistance, offering a potential anti-cancer target.

Area of Science:

  • Oncology
  • Cell Biology
  • Cancer Research

Background:

  • The tumor microenvironment (TME) is a complex ecosystem supporting tumor initiation, progression, and metastasis.
  • Cancer-associated fibroblasts (CAFs) are key cellular components within the TME, maintaining its structural and functional integrity.
  • Molecular mechanisms of CAF differentiation and CAF-tumor crosstalk are not fully understood.

Purpose of the Study:

  • To review the pivotal roles of the mitogen-activated protein kinase (MAPK) signaling pathway in regulating CAF phenotypes.
  • To explore MAPK signaling's influence on tumor cell behavior and CAF-tumor crosstalk.
  • To discuss the therapeutic potential of targeting MAPK signaling in anti-cancer strategies.

Main Methods:

  • Literature review focusing on MAPK signaling pathways.
  • Analysis of research on CAF differentiation and function.
  • Examination of studies on CAF-tumor interactions and therapy resistance.

Main Results:

  • MAPK signaling is central to CAF differentiation and educates fibroblasts into a pro-tumorigenic phenotype.
  • Activated MAPK signaling in CAFs and tumor cells correlates with tumor progression and immune evasion.
  • MAPK signaling facilitates therapy-resistant niches through intercellular reactivation of oncogenic pathways.

Conclusions:

  • MAPK signaling critically regulates CAF phenotypes, tumor cell behavior, and CAF-tumor crosstalk.
  • Targeting MAPK signaling presents a promising therapeutic strategy to overcome limitations in current anti-cancer treatments.
  • Understanding MAPK's role in the TME is crucial for developing novel cancer therapies.
Keywords:
CAF-cancer cell interactomeCancer-associated fibroblastImmunosuppressive nicheMAPK signaling pathwayStromal shieldTumor microenvironment

More Related Videos

A Novel Stromal Fibroblast-Modulated 3D Tumor Spheroid Model for Studying Tumor-Stroma Interaction and Drug Discovery07:20

A Novel Stromal Fibroblast-Modulated 3D Tumor Spheroid Model for Studying Tumor-Stroma Interaction and Drug Discovery

Published on: February 28, 2020

Isolation of Primary Cancer-Associated Fibroblasts from a Syngeneic Murine Model of Breast Cancer for the Study of Targeted Nanoparticles08:02

Isolation of Primary Cancer-Associated Fibroblasts from a Syngeneic Murine Model of Breast Cancer for the Study of Targeted Nanoparticles

Published on: May 14, 2021

Related Concept Videos

MAPK Signaling Cascades01:07

MAPK Signaling Cascades

Mitogen-activated protein kinase, or MAPK pathway, activates three sequential kinases to regulate cellular responses such as proliferation, differentiation, survival, and apoptosis. The canonical MAPK pathway starts with a mitogen or growth factor binding to an RTK. The activated RTKs stimulate Ras, which recruits Raf or MAP3 Kinase (MAPKKK), the first kinase of the MAPK signaling cascade. Raf further phosphorylates and activates MEK or MAP2 Kinases (MAPKK), which in turn phosphorylates MAP...
Interactions Between Signaling Pathways01:19

Interactions Between Signaling Pathways

Signaling cascades usually lack linearity. Multiple pathways interact and regulate one another, allowing cells to integrate and respond to diverse environmental stimuli.
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The Tumor Microenvironment02:17

The Tumor Microenvironment

Every normal cell or tissue is embedded in a complex local environment called stroma, consisting of different cell types, a basal membrane, and blood vessels. As normal cells mutate and develop into cancer cells, their local environment also changes to allow cancer progression. The tumor microenvironment (TME) consists of a complex cellular matrix of stromal cells and the developing tumor. The cross-talk between cancer cells and surrounding stromal cells is critical to disrupt normal tissue...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...